This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Novartis (NVS) Q4 Earnings & Sales Top on Cosentyx, Entresto
by Zacks Equity Research
Novartis (NVS) announced strong results for the fourth quarter as earnings and sales both beat estimates driven by Cosentyx and Entresto sales which more than offset the decline in Gleevec sales.
What's in the Cards for Biogen (BIIB) This Earnings Season?
by Zacks Equity Research
On the Q4 call, investor focus will be on the impact of Roche's newly launched drug, Ocrevus on Biogen's (BIIB) MS franchise, and Spinraza's performance.
Amgen/Allergan's Avastin Biosimilar Secures EU Approval
by Zacks Equity Research
Amgen (AMGN) and Allergan's Mvasi - a biosimilar version of Roche's cancer drug, Avastin - gets marketing approval in the EU.
Cancer Space Update: Label Expansions, Data Readouts in Focus
by Zacks Equity Research
This week the cancer space was abuzz with news of label expansion of Kyprolis, Lynparza and Kymriah and positive data readouts for Cabometyx and Keytruda.
BioLineRx Cancer Drug Positive as Monotherapy in Phase IIa
by Zacks Equity Research
BioLineRx (BLRX) posts encouraging partial results from the monotherapy portion of a phase IIa COMBAT study, assessing its lead pipeline candidate, BL-8040, for pancreatic cancer patients.
Merck Strong on Confirmatory Phase III Lung Cancer Study
by Zacks Equity Research
Merck's (MRK) Keytruda in combination with Eli Lilly's Alimta and carboplatin meet dual primary endpoints in a confirmatory phase III study for the first-line treatment of lung cancer.
Ophthotech Begins Phase II Zimura Study in Stargardt Disease
by Zacks Equity Research
Ophthotech (OPHT) is focusing on Zimura following the failure of the Fovista studies.
Exelixis, Ipsen Report Positive Results on Lead Cancer Drug
by Zacks Equity Research
Exelixis (EXEL) and Ipsen announce detailed results from the late stage study of lead drug Cabometyx in patients with previously treated advanced HCC.
Will Amgen (AMGN) Continue to Tread Growth Path This Year?
by Zacks Equity Research
Amgen (AMGN) stock outperformed the industry in 2017. We will have to wait and see if it can keep the momentum alive in 2018.
Why is Puma (PBYI) Stock Up More than 150% in a Year's Time?
by Zacks Equity Research
Puma's (PBYI) shares jump in a year's time on its cancer drug Nerlynx's approval in the United States coupled with strategic collaborations.
Prothena (PRTA) Tumbles 18% in a Year: What Lies Ahead?
by Zacks Equity Research
Prothena's (PRTA) stock tumbles more than 18% due to a pipeline setback. The company depends heavily on the success of its two candidates.
Roche MS Drug Ocrevus Gets Marketing Authorization in Europe
by Zacks Equity Research
Roche's (RHHBY) multiple sclerosis drug Ocrevus gets approval in Europe thereby boosting its neuroscience portfolio. The drug is already approved in the United States.
FDA Approvals Surge in 2017: Here's a Look at the Numbers
by Arpita Dutt
There was a significant surge in FDA approvals in 2017 with the regulatory body giving its nod to 46 novel drugs plus gene-based therapies like Novartis's (NVS) Kymriah. Here is a closer look at the numbers and what lies ahead.
GE Healthcare Partners Roche for Improved Critical Care
by Zacks Equity Research
General Electric Company's (GE) segment GE Healthcare will now help to create a digital platform with Roche to advance medicinal treatments particularly for cancer and critical care patients.
Exelixis Amends Cabozantinib-Tecentriq Phase Ib Trial
by Zacks Equity Research
Exelixis, Inc. (EXEL) announced an amendment to the protocol for the phase Ib trial of cabozantinib combined with Tecentriq whereby there will be four new expansion cohorts to the trial.
ImmunoGen Starts Phase I Study on Leukemia Candidate IMGN632
by Zacks Equity Research
ImmunoGen (IMGN) begins a phase I study to evaluate its anti-CD123 antibody-drug conjugates, IMGN632, for treating patients with hematological malignancies.
Cancer Space Update: New Regulatory Status for 3 Major Drugs
by Zacks Equity Research
Merck's Keytruda receives approval in Japan for bladder cancer. Seattle Genetics' Adcetris and Novartis' Kisqali get regulatory status updates from the FDA.
Celsion's Phase I/II Cancer Study Initiation Gets FDA Nod
by Zacks Equity Research
Celsion's (CLSN) plan for phase I/II study to evaluate DNA-based immunotherapy, GEN-1, in ovarian cancer gets FDA approval and clearance for initiation.
Pharma Stock Roundup: Allergan Announces Job Cuts, Pfizer Inks Deals
by Arpita Dutt
In a relatively slow week, Allergan's (AGN) job cut announcement remained the key highlight while Pfizer's collaboration agreements with Sangamo and Arvinas were also in focus.
3 Large-Cap Pharma Stocks to Watch Out for This New Year
by Zacks Equity Research
We take a look at a few Large Cap drug stocks with a favorable combination of Zacks Rank and VGM Score. The stocks are poised to carry on their bull run this year too.
Can AbbVie (ABBV) Stock Keep the Momentum Alive in 2018?
by Zacks Equity Research
AbbVie Inc. (ABBV) shares are expected to be northbound in 2018, carrying on the momentum achieved last year.
Novartis Gets Second Breakthrough Designation for Kisqali
by Zacks Equity Research
Novartis (NVS) announces that the FDA has granted the second breakthrough designation to breast cancer drug, Kisqali, for the initial endocrine-based treatment of pre- or peri-menopausal women with HR+/HER2- advanced or metastatic breast cancer.
Foreign Stock Roundup: Roche to Buy Ignyta for $1.7B; Shell to Acquire First Utility
by Swarup Gupta
Global markets traversed a holiday shortened week marked by thin trading volumes.
3 Biotech and Pharma Stocks with FDA Catalysts this January
by Arpita Dutt
2017 saw the FDA approving 46 novel drugs as well as path-breaking treatments like Novartis's (NVS) Kymriah and Gilead's Yescarta. Here is a look at three companies expecting a decision this January.
The Zacks Analyst Blog Highlights: Johnson and Johnson, AbbVie, Roche's, AstraZeneca and Novo-Nordisk A/S
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson and Johnson, AbbVie, Roche's, AstraZeneca and Novo-Nordisk A/S